Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC
Status:
Completed
Trial end date:
2017-07-04
Target enrollment:
Participant gender:
Summary
"Immuncell-LC" in aspects of therapeutic efficacy and safety when administered with Nexavar
to advanced Hepatocellular carcinoma patients when compared with the control group who did
not receive administration of the drug.